These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38576104)

  • 1. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
    Shalmon D; Bar-Ilan E; Peled A; Geller S; Bar J; Schwartz N; Sprecher E; Pavlovsky M
    Acta Derm Venereol; 2024 Apr; 104():adv26663. PubMed ID: 38576104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
    Lambadiari V; Kountouri A; Kousathana F; Korakas E; Kokkalis G; Theotokoglou S; Palaiodimou L; Katsimbri P; Ikonomidis I; Theodoropoulos K; Papadavid E
    BMC Endocr Disord; 2021 Feb; 21(1):23. PubMed ID: 33573656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
    Phan K; Charlton O; Smith SD
    Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
    Jha A; Misra A; Gupta R; Ghosh A; Tyagi K; Dutta K; Arora B; Durani S
    Diabetes Metab Syndr; 2020; 14(3):213-216. PubMed ID: 32172176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients.
    Armanious M; AbuHilal M
    J Cutan Med Surg; 2021; 25(2):163-168. PubMed ID: 33176433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid induced by vildagliptin: a report of three cases.
    Béné J; Jacobsoone A; Coupe P; Auffret M; Babai S; Hillaire-Buys D; Jean-Pastor MJ; Vonarx M; Vermersch A; Tronquoy AF; Gautier S
    Fundam Clin Pharmacol; 2015 Feb; 29(1):112-4. PubMed ID: 24861252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
    Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
    JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
    Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
    Front Immunol; 2022; 13():942131. PubMed ID: 35958564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.
    Plaquevent M; Tétart F; Fardet L; Ingen-Housz-Oro S; Valeyrie-Allanore L; Bernard P; Hebert V; Roussel A; Avenel-Audran M; Chaby G; D'Incan M; Ferrier-Le-Bouedec MC; Duvert-Lehembre S; Picard-Dahan C; Jeudy G; Collet E; Labeille B; Morice C; Richard MA; Bourgault-Villada I; Litrowski N; Bara C; Mahe E; Prost-Squarcioni C; Alexandre M; Quereux G; Bernier C; Soria A; Thomas-Beaulieu D; Pauwels C; Dereure O; Benichou J; Joly P; ;
    J Invest Dermatol; 2019 Apr; 139(4):835-841. PubMed ID: 30543900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases.
    Yoshiji S; Murakami T; Harashima SI; Ko R; Kashima R; Yabe D; Ogura M; Doi K; Inagaki N
    J Diabetes Investig; 2018 Mar; 9(2):445-447. PubMed ID: 28520234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliptin-induced bullous pemphigoid.
    Ganeva M; Gancheva T; Manuelyan K; Hristakieva E
    Int J Clin Pharmacol Ther; 2024 Feb; 62(2):89-95. PubMed ID: 38032147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Cohort Study.
    Magdaleno-Tapial J; Valenzuela-Oñate C; Esteban Hurtado Á; Ortiz-Salvador JM; Subiabre-Ferrer D; Ferrer-Guillén B; Giacaman-von der Weth M; García-Legaz Martínez M; Martínez-Domenech Á; Hernández-Bel P; Esteve-Martínez A; Pérez-Pastor G; Zaragoza-Ninet V; García-Rabasco A; Martínez-Aparicio A; Sánchez-Carazo JL; Pérez-Ferriols A; Alegre-de Miquel V
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):249-253. PubMed ID: 31864538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases.
    Molina-Guarneros JA; Sainz-Gil M; Sanz-Fadrique R; García P; Rodríguez-Jiménez P; Navarro-García E; Martin LH
    Int J Clin Pharm; 2020 Apr; 42(2):713-720. PubMed ID: 32140915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database.
    Reolid A; Muñoz-Aceituno E; Rodríguez-Jiménez P; González-Rojano E; Llamas-Velasco M; Fraga J; Daudén E
    Int J Dermatol; 2020 Feb; 59(2):197-206. PubMed ID: 31605541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
    Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
    J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.